Nasdaq
$2.17▼ 0.46%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $138.2MShares out 63.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 10.16After-hours26.10.17 06:008-KKey event#●●●#●●●
TuHURA Biosciences, Inc./NV
On October 9, 2026, TuHURA Biosciences drew an additional $650,000 under its existing revolving credit facility with Parkview Holdings One LLC. The funds are intended for general corporate purposes, and the facility, which has a maximum availability of $50 million, matures on April 21, 2031.…more
$2.17-0.46%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.24After-hours26.09.25 06:008-KKey event
TuHURA Biosciences, Inc./NV
On September 21, 2026, TuHURA Biosciences, Inc. borrowed an additional $650,000 under its existing revolving credit facility with Parkview Holdings One LLC. The company intends to use these funds for general corporate purposes.…more
$2.17-0.46%vs prev closeView filingShare - 9.17After-hours26.09.18 06:008-KKey event
TuHURA Biosciences, Inc./NV
On September 14, 2026, TuHURA Biosciences borrowed an additional $650,000 under its existing loan agreement with Parkview Holdings One LLC. The company intends to use these funds for general corporate purposes.…more
$2.17-0.46%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.13Pre-market26.10.13 20:48#●●●#●●●
TuHURA Biosciences Secures US Patent For TBS-2025
TuHURA Biosciences has been granted a U.S. patent for its VISTA-inhibiting antibody, TBS-2025. The patent covers various therapeutic applications, including cancer, autoimmune diseases, and infections, extending protection until 2042.…more
$2.17-0.46%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.5Pre-market26.10.05 20:48
●●●●●●●● ●●●●● ●●●●●●
TuHURA Biosciences has been granted a U.S. patent for the administration of DOR antagonists to improve cancer immunotherapy outcomes. The patent covers methods to reprogram the immunosuppressive tumor microenvironment to enhance treatment efficacy.…more
$2.17-0.46%vs prev closeShareBenzinga - 9.14Pre-market26.09.14 20:49
●●●●●●●● ●●●●● ●●●●●●
TuHURA Biosciences has received FDA clearance to proceed with a Phase 1b clinical trial for its TBS-2025 antibody targeting specific blood cancers. The study will evaluate the safety and efficacy of the treatment in patients who have failed prior therapies.…more
$2.17-0.46%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report